Monophasic HA Filler + Lidocaine Corrects Nasolabial Folds

Share this content:
Monophasic HA Filler + Lidocaine Corrects Nasolabial Folds
Monophasic HA Filler + Lidocaine Corrects Nasolabial Folds

THURSDAY, Feb. 9, 2017 (HealthDay News) -- The monophasic hyaluronic acid (HA) filler with lidocaine, Dermalax implant plus (PLUS), is not inferior to the biphasic HA Restylane Sub-Q (Sub-Q) for correcting nasolabial folds (NLFs), according to a study published online Feb. 1 in the Journal of Cosmetic Dermatology.

Joon Hyuk Suh, M.D., from the Chung-Ang University College of Medicine in Seoul, South Korea, and colleagues enrolled 52 patients with visible NLFs in a randomized multicenter trial. Participants were injected with PLUS in one NLF and with Restylane Sub-Q in the other. Cosmetic changes were assessed in participants at two, eight, 12, 16, and 24 weeks. The 5-point Wrinkle Severity Rating Scale (WSRS) was used to rate wrinkle severity.

The researchers found that the mean improvement in the WSRS at week 24 versus baseline was 1.06 ± 0.54 and 0.69 ± 0.58 for the PLUS side and Sub-Q side, respectively. Within 30 minutes after the procedure, the average values of pain evaluated by self-assessment 100-mm visual analogue score scale were 14.65 ± 16.23 and 38.29 ± 27.27 in the PLUS and Sub-Q groups, respectively. Both fillers were well tolerated, with mild adverse reactions.

"We confirmed that the monophasic HA containing pre-incorporated lidocaine (PLUS) is not inferior to well-studied biphasic HA (Sub-Q) in correcting severe nasolabial folds for 24 weeks, and [is] less painful than biphasic HA not containing lidocaine," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »